BRCA1 in Triple-Negative Breast Cancer: A Double-Edged Sword for Prognosis and Precision Therapy | ||||
| Egyptian Journal of Cancer and Biomedical Research | ||||
| Articles in Press, Accepted Manuscript, Available Online from 26 July 2025 | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/jcbr.2025.371019.1391 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Nancy H Amin; Noura A. A. Ebrahim   ; Mustafa A Hussein
| ||||
| Oncologic Pathology Department, National Cancer Institute, Cairo University | ||||
| Abstract | ||||
| Background:Triple-negative breast cancer (TNBC) is an aggressive subtype lacking estrogen receptor (ER), progesterone receptor (PR), and HER2 expression. The BRCA1 gene encodes a tumor suppressor protein critical for homologous recombination (HR) DNA repair, playing a key role in TNBC progression and treatment response. Aim: To assess BRCA1 protein expression in TNBC and evaluate its impact on survival status. Material & methods:This study retrospectively analyzed 80 TNBC cases to assess BRCA1 protein expression through immunohistochemistry and its correlation with clinicopathologic features, recurrence patterns, and survival outcomes. Kaplan-Meier survival analysis and Cox proportional hazards regression were used for statistical evaluation. Results: Findings revealed that low BRCA1 expression was significantly associated with high tumor grade, lymphovascular invasion, and poor disease-free and overall survival. Conversely, high BRCA1 expression correlated with early-stage disease, smaller tumor sizes, and improved survival outcomes. Conclusion:These results highlight the impact of low BRCA1 expression on TNBC aggressiveness and its potential role as a prognostic biomarker. Further research integrating multi-omics approaches may improve personalized treatment strategies for management of BRCA1-associated TNBC. | ||||
| Keywords | ||||
| BRCA1; PARP inhibitors; prognostic biomarker; TNBC | ||||
|
Statistics Article View: 47 |
||||
